GlassScriptPhysician profile
Joan Taddei
NPI 1760148381
$4,483.99
in general payments reported to CMS, 2019-2025
25 companies · $2,791 in 2025
The $2,791 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,693 · 2025: $2,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,455 · Education: $29.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,454.52 |
| Education | $29.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $675.47 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $630.99 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $417.80 | 2024-2025 | Xifaxan |
| Pfizer INC. | $305.75 | 2025 | |
| Lilly USA, LLC | $301.75 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $274.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $270.94 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $247.57 | 2025 | Tremfya |
| Qol Medical, LLC | $243.08 | 2024-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $153.54 | 2024-2025 | |
| Genzyme Corporation | $132.30 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $127.11 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $110.22 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $108.38 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $95.55 | 2024-2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $90.14 | 2025 | Injectafer |
| Evoke Pharma, INC. | $54.55 | 2024-2025 | |
| Novo Nordisk INC | $51.82 | 2025 | Wegovy |
| Celltrion USA INC. | $48.88 | 2024 | Zymfentra, Vegzelma |
| Merck Sharp & Dohme LLC | $43.20 | 2024 | Dificid |
| Shield Therapeutics INC | $26.47 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.06 | 2024 | Ultomiris |
| Amgen INC. | $20.29 | 2025 | Uplizna |
| Teleflex LLC | $17.83 | 2024 | Solesta |
| Gilead Sciences, INC. | $15.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Taddei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.